LPTX Leap Therapeutics Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: LPTX

Price (delayed)

$3.19

Market cap

$81.66M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$3.98

Enterprise value

$10.06M

Leap Therapeutics is focused on developing targeted and immuno-oncology therapeutics. Leap's most advanced clinical candidate, DKN-01, is a humanized monoclonal antibody targeting the Dickkopf-1 (DKK1) protein, a Wnt pathway modulator. ...

Highlights
LPTX's debt has dropped by 100% year-on-year
The EPS has increased by 30% since the previous quarter and by 17% year-on-year
The equity has declined by 16% since the previous quarter but it has grown by 2.2% year-on-year
Leap Therapeutics's net income has decreased by 49% YoY
The quick ratio is down by 24% since the previous quarter and by 7% year-on-year
Sector: Healthcare
Industry: Biotechnology
Website: http://www.leaptx.com
Peers: OMER OMGA

Key stats

What are the main financial stats of LPTX
Market
Shares outstanding
25.6M
Market cap
$81.66M
Enterprise value
$10.06M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
1.36
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Earnings
Revenue
$0
EBIT
-$81.41M
EBITDA
-$81.4M
Free cash flow
-$43.75M
Per share
EPS
-$3.98
Free cash flow per share
-$2.14
Book value per share
$2.35
Revenue per share
$0
TBVPS
$3.56
Balance sheet
Total assets
$72.83M
Total liabilities
$12.68M
Debt
$0
Equity
$60.14M
Working capital
$58.91M
Liquidity
Debt to equity
0
Current ratio
5.64
Quick ratio
5.71
Net debt/EBITDA
0.88
Margins
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Efficiency
Return on assets
-90.9%
Return on equity
-133.2%
Return on invested capital
N/A
Return on capital employed
-135.4%
Return on sales
N/A
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

LPTX stock price

How has the Leap Therapeutics stock price performed over time
Intraday
0.63%
1 week
-1.85%
1 month
26.09%
1 year
-91.39%
YTD
-23.04%
QTD
19.92%

Financial performance

How have Leap Therapeutics's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$87.04M
Net income
-$81.41M
Gross margin
N/A
Net margin
N/A
The company's operating income has shrunk by 53% YoY
Leap Therapeutics's net income has decreased by 49% YoY

Growth

What is Leap Therapeutics's growth rate over time

Valuation

What is Leap Therapeutics stock price valuation
P/E
N/A
P/B
1.36
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The EPS has increased by 30% since the previous quarter and by 17% year-on-year
LPTX's P/B is 36% above its last 4 quarters average of 1.0 but 35% below its 5-year quarterly average of 2.1
The equity has declined by 16% since the previous quarter but it has grown by 2.2% year-on-year

Efficiency

How efficient is Leap Therapeutics business performance
The return on equity has dropped by 89% year-on-year
The ROA has contracted by 47% YoY

Dividends

What is LPTX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for LPTX.

Financial health

How did Leap Therapeutics financials performed over time
The quick ratio is down by 24% since the previous quarter and by 7% year-on-year
The current ratio has declined by 24% since the previous quarter and by 7% year-on-year
LPTX's debt is 100% smaller than its equity
LPTX's debt has dropped by 100% year-on-year
The equity has declined by 16% since the previous quarter but it has grown by 2.2% year-on-year

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.